Nantong Large-Molecular Drug Commercialization Site focuses on commercial manufacturing of antibodies, proteins and large-molecular drugs. It runs 5 conventional drug substance lines (200L/500L/2000L single-use bioreactors) and 1 perfusion line, together with vial and pre-filled syringe lines with batch capacities of 100,000 vials and 64,000 syringes. In full compliance with China GMP, FDA and EMA requirements, we offer complete services from process development to mass production. With proven strengths in perfusion process scale-up, we supply reliable and efficient manufacturing solutions for global partners.

An all-in-one ADC platform of Thousand Oaks Biologics covering naked antibody production, conjugation and formulation filling. Fitted with 200L–2000L single-use bioreactors, diverse conjugation systems and OEB-5 grade isolator filling lines, it achieves a single-batch capacity of 120,000 vials. The unified on-site workflow minimizes intermediate transfer risks. Compatible with Cytiva, Merck and other mainstream equipment, it delivers flexible, high-efficiency manufacturing services in line with international criteria for ADC development.

JSBio’s Phase I R&D and manufacturing site has over a decade of experience in cell culture media. Covering 9,908 ㎡, it is equipped with 100kg, 200kg and 400kg fully automated lines, integrating R&D, pilot and commercial production. We supply high-quality media to biopharma firms in China and incubate new technologies. With mature core processes, we excel in formulation optimization and serum-free culture, complying with JSBio’s proprietary R&D system and international quality standards. Enabling seamless lab-to-industry technology transfer, our platform has supported commercial production of multiple blockbuster biotherapeutics globally, demonstrating the outstanding quality and competitiveness of our products.

As one of Asia’s leading manufacturing sites for animal-origin-free cell culture media, CCM2 focuses on large-scale, high-quality media production. Equipped with fully automated conical blending, low-temperature milling and closed integrated production processes, the site delivers a single-batch capacity of 6 tons and an annual output exceeding 10 million liters. Supported by rigorous cGMP compliance and full batch traceability systems, we ensure superior product consistency and stability. The site provides critical raw material solutions for global biopharmaceutical enterprises, supporting end-to-end cell culture process development and manufacturing from clinical trials to commercial launch.

A key component of JSBio’s global layout, this site focuses on supplying high-end cell culture media for the Asian market. Covering 16,827 ㎡, it operates 50kg, 850kg and 6,000kg production lines to enable flexible multi-specification manufacturing. Continuous process optimization strengthens the international competitiveness of our media products. We provide cGMP-compliant, animal-origin-free media for clients in South Korea and the broader APAC region, fueling the rapid development of the regional biopharmaceutical industry.

Located in Shanghai Zhangjiang Pharma Valley, JSBio’s subsidiary Ginspire features 1,008 ㎡ of professional R&D space. Backed by the Group’s in-depth CRDMO experience, it delivers full-process early-stage R&D services for innovative drugs. Its service scope covers molecular design optimization, antibody discovery and engineering, ADC linker-toxin screening and conjugation, druggability assessment, PK/PD evaluation, sample preparation, structural and functional characterization, and novel formulation development. Empowered by AI prediction, ADC and antibody engineering platforms, Ginspire offers one-stop development solutions for mAbs, bispecifics, ADCs and other complex biomolecules, solving core R&D challenges and improving clinical translation success rates.

Located in Pleasanton, United States, Thousand Oaks Biologics serves as JSBio’s strategic and technical hub for the Americas. This 1,000 ㎡ site features an international professional team, focusing on high-titer cell line development and custom cell culture media design to deliver localized technical services for North American clients. Integrating the Group’s full-chain CMC capabilities, it expands global business layouts, synergizes Sino-U.S. R&D resources, and continuously strengthens JSBio’s global technological influence in the biopharmaceutical industry.